By staff writers

November 7, 2019 -- Thermo Fisher Scientific is working with Owlstone Medical to develop noninvasive breath sample tests in a collaboration that will include the discovery and validation of new biomarkers for the earlier detection of disease.

Based in Cambridge, U.K., Owlstone offers its Breath Biopsy platform and developed the ReCiva breath sampler for collecting "volatile organic compounds" in breath, enabling chemical analysis and an understanding of underlying metabolic processes. The company sees the breathalyzer as being applicable across conditions, but it has focused its research on cancer, inflammatory disease, and infectious disease.

The collaboration will involve the integration of Thermo Fisher's Q Exactive GC Hybrid Quadrupole-Orbitrap gas chromatography mass spectrometry (GC-MS) technology into Owlstone's Breath Biopsy platform. The plan is to make the analyzer a standard part of Owlstone's work, which includes research for pharmaceutical and academic clients. Owlstone is currently working with AstraZeneca and GlaxoSmithKline, among other pharmaceutical companies.

Thermo Fisher and Owlstone plan to jointly market the breath testing platform globally.

AMP roundup: Vendors showcase same-day NGS, faster prep, DNA/RNA combos
BALTIMORE - Bruce Carlson, publisher of Kalorama Information, is on the ground at the Baltimore Convention Center for this week's Association for Molecular...
Thermo Fisher seals companion test deal with Lilly
Thermo Fisher Scientific has signed an agreement to develop its Oncomine Dx for use as a companion test with Lilly's LOXO-292 drug in non-small cell lung...
Thermo Fisher flags data for tumor mutation test
Thermo Fisher Scientific will showcase new research involving its Oncomine tumor mutation load assay and how it relates to cancer immunotherapy response...
Thermo Fisher Scientific unveils products at AACC 2019
Thermo Fisher Scientific is showcasing a benchtop automated reading and incubation system for antimicrobial susceptibility testing and new sustainable...

Copyright © 2019

Last Updated np 11/7/2019 6:29:36 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.